Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial

Many Canadians received a novel AS03-adjuvanted vaccine during the 2009 influenza A/H1N1 pandemic. Longer term implications of adjuvant use were unclear: would anti-H1N1 immune responses persist at high levels and, if so, could that result in increased or unusual adverse effects upon re-exposure to...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheifele, David W., Dionne, Marc, Ward, Brian J., Cooper, Curtis, Vanderkooi, Otto G., Li, Yan, Halperin, Scott A., Influenza Research Network, PHAC/CIHR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667929/
https://www.ncbi.nlm.nih.gov/pubmed/23570051
http://dx.doi.org/10.4161/hv.22619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667929/
https://www.ncbi.nlm.nih.gov/pubmed/23570051
http://dx.doi.org/10.4161/hv.22619

Ejemplares similares